Navigation Links
New type of drug shrinks primary breast cancer tumors significantly in just 6 weeks
Date:4/17/2008

Berlin, Germany: A drug that targets the cell surface receptors that play an important role in many types of cancer can bring about significant tumour regression in breast cancer after only six weeks of use, a scientist told the 6th European Breast Cancer Conference (EBCC-6) today (Thursday 17 April). Dr. Angel Rodriguez, from the Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, USA, said that the work demonstrated for the first time that the tyrosine kinase inhibitor lapatinib could decrease tumour-causing breast cancer stem cells in the primary breast cancers of women receiving neoadjuvant treatment (treatment given before the primary surgery for the disease).

Dr. Rodriguez and colleagues studied 45 patients with locally advanced breast cancer in which the gene HER-2 was over-expressed. The patients received lapatinib for six weeks, followed by a combination of weekly trastuzumab and three-weekly docetaxel, given over 12 weeks, before primary surgery. Biopsies were performed at the time of diagnosis and also after six weeks of lapatinib and cells from the tumours were obtained and analyzed.

We saw significant tumour regression after six weeks of single agent lapatinib, said Dr. Rodriguez. Bi-dimensional tumour measurements showed a median decrease of minus 60.8%. We had previously showed that tumour-causing breast cancer stem cells were resistant to conventional preoperative chemotherapy; indeed, residual cancers that were exposed to such chemotherapy showed an increase in tumour-causing cells and enhanced tumour initiation by the formation of mammospheres, small tumours that form when tumour-causing cells are cultured in a test tube, which reflect the capacity of the cells to self-renew. So we were excited to see that the results with lapatinib were different.

Dr. Rodriguezs results suggest that specific signalling inhibitors of the pathways responsible for stem cell self-renewal could provide a poss
'/>"/>

Contact: Mary Rice
mary@mrcommunication.org
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2

Related biology news :

1. Single-largest biodiversity survey says primary rainforest is irreplaceable
2. UNH becomes first university in nation to use landfill gas as primary energy source
3. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
4. Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
5. Pregnant patients lose out in breast cancer treatment; a new approach is needed
6. Improving care and knowledge in translational research to fight breast cancer
7. Evidence now suggests eating soy foods in puberty protects against breast cancer
8. T-cadherin affects blood vessel growth in breast cancer, hormone from fat cells may play a role
9. MU researcher links hormone replacement therapy to breast cancer
10. Gene variant increases breast cancer risk
11. High levels of estrogen associated with breast cancer recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2015)... PRINCETON, N.J. , Aug. 18, 2015 ... be a key contributor to the Submission ... hosted by IRISS, a non-profit forum. Dedicated to ... IRISS provides a neutral platform for industry, ... to share information and work towards a ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
(Date:8/12/2015)... Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that four of its fingerprint ... have officially been named FIDO Certified™ by the ... the certification, Synaptics, Natural ID™ fingerprint solutions are ... Framework (UAF) standard and are interoperable among other ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... , June 4, 2013  With invasions of computer systems ... Identify Security Software Inc. ( www.identifyss.com ) today announced ... http://photos.prnewswire.com/prnh/20130604/FL25436LOGO ) "Identify Security Software ... way for businesses and institutions to manage and control ...
... and NEW ORLEANS , June 3, 2013 ... Microsoft demonstrates an FPC fingerprint touch sensor in combination with a ... demonstrations showcase a number of innovative online use cases using FPC,s ... to sign on to their Microsoft account, make online payments and ...
... the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore has ... protein linked to stem cell-like behavior in terminal-stage chronic ... that may extend the survival of these patients. ... Proceedings of the National Academy of Sciences , is ...
Cached Biology News:Identify Security Software to Make Cyberspace Secure 'Once And For All' 2Identify Security Software to Make Cyberspace Secure 'Once And For All' 3Fingerprint Cards (FPC) Demonstrates Fingerprint Biometric Touch Sensor for Microsoft Windows 8.1 2Singapore research team identifies new drug target in deadly form of leukemia 2
(Date:8/31/2015)... Israel , Aug. 31, 2015 ... Dario™ Diabetes Management Solution, today announced it recently ... million. Funds will be used to support the ... the Dario, a mobile, cloud-based, diabetes management solution ... stylish, ,all-in-one, pocket-sized, blood glucose monitoring device, and ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option ... the first commercially available new FDA approved system in the last 14 years, and ... the high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of ...
(Date:8/28/2015)... 2015 According to a new ... Storage Systems, Thawing Equipment, Alarms), by Biospecimen (Human Tissue, ... End User - Global Forecast to 2020", published by ... USD 3,731.03 Million by 2020 from USD 2,150.48 Million ... 2015 and 2020. Browse 74 Tables ...
(Date:8/28/2015)... ... 2015 , ... Riordan-McKenna Institute founders, stem cell ... the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed by Amniotic Therapies ... knee wound. , The case involved a 78-year-old male, who presented with a ...
Breaking Biology Technology:LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4
... At a meeting of the,Board of ... ), held today, a dividend of ... outstanding shares of Preferred Stock was,declared ... stockholders of record at the close,of ...
... Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced ... ended September 30, 2007. Net,revenues totaled $7,373,770 for the ... period in 2006. Gross profit decreased by 2.66% due ... sales from Aida,s,transfusion and injection forms of etimicin sulfate ...
... Million Financing, WOBURN, Mass., Nov. 15 BioVex ... the treatment and,prevention of cancer and infectious disease, announced ... the completion of a,venture debt transaction, raising a total ... the capital to complete its preparations for, and,to commence, ...
Cached Biology Technology:Aida Files 10Q 2Aida Files 10Q 3Aida Files 10Q 4BioVex Closes Second Round of Series E Financing 2
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Evolutionarily conserved signaling intermediate in Toll pathway...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Biology Products: